氨酸装载在β-环氧的金属有机框架中,以提高稳定性和可溶性
Hui Zhang1,2,3, Liyun Dong1,2,3, Tao Guo4
1Anhui University of Chinese Medicine, Hefei, 230012, China.
AAPS PharmSciTech
|June 11, 2024
概括
我们开发了一种新的β-cyclodextrin金属有机框架 (β-CD-MOF) 来提高黄蛋白 (Lut) 的稳定性和可溶性. 由此产生的Lut@β-CD-MOF复合物为营养和医疗保健应用提供了增强的特性.
科学领域:
- 材料科学 材料科学 材料科学
- 纳米技术纳米技术
- 营养科学 营养科学
背景情况:
- 氨酸 (Lut) 是一种重要的营养补充剂,具有对眼睛健康的抗氧化和抗炎作用.
- 对于提高黄蛋白的稳定性和可溶性,以获得有效的配方,仍然存在挑战.
- 金属有机框架 (MOF) 为封装和改善活性化合物的特性提供了潜力.
研究的目的:
- 制造和评估一种食品级的β-cyclodextrin金属有机框架 (β-CD-MOF) 用于蛋白封装.
- 评估β-CD-MOF封装对黄蛋白稳定性,溶解性和水友性的影响.
- 为了确认蛋白在β-CD-MOF结构中的成功封装.
主要方法:
- 制造一个高度多孔的β-CD-MOF.
- 在β-CD-MOF中封装黄蛋白,形成Lut@β-CD-MOF.
- 使用分子对接,FTIR,XRD,TGA和拉曼光谱进行表征.
- 评估高温 (40°C,60°C,70°C) 的稳定性和在37°C的溶解性.
- 测量水接触角度以确定水友性.
主要成果:
- 与自由黄蛋白,Lut@γ-CD-MOF,Lut@β-CD和在各种温度下商用产品相比,Lut@β-CD-MOF的稳定性明显提高.
- 在37°C的β-CD-MOF中封装后,黄蛋白的水溶性增加了26.8倍.
- 对Lut@β-CD-MOF.观察到增强的水友性.
- 鉴定证实了β-CD-MOF结构内的蛋白封装成功.
结论:
- 开发的β-CD-MOF有效地提高了黄蛋白的稳定性和可溶性.
- Lut@β-CD-MOF为需要改善黄蛋白输送的营养和医疗保健应用提供了一个有前途的配方.
- 这项研究突出了β-CD-MOF作为难以溶解和不稳定的化合物的先进输送系统的潜力.
更多相关视频
相关概念视频
Extraction: Advanced Methods
446
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
446
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
198
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
198


